<h4>Abstract</h4>Infections remain a challenge during treatment of patients with multiple myeloma (MM) with anti-B-cell maturation antigen (BCMA) and anti-G protein-coupled receptor class C group 5 member D (GPRC5D) bispecific antibodies (bsAbs). The gene discussed is TNFRSF17; the disease is plasma cell myeloma.